Oncolytic viral vectors and uses thereof
AssigneeOncorus, Inc.
InventorsKenneth P. Greenberg, Mitchell H. Finer
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to recombinant viral vectors for the treatment and prevention of cancer. Oncolytic viral vectors incorporate one or more of the following features: viral replication restriction by insertion of tumor-suppressive microRNA (miRNA) target sequences into the viral genome; disruption of oncogenic miRNA function; cancer microenvironment remodeling; and cancer cell targeting by incorporation of protease-activated antibodies into the viral particle.
Claims31
A recombinant herpes simplex virus (HSV) comprising at least one copy of a micro-RNA (miR)-124 target sequence inserted into the ICP4 locus of the recombinant HSV genome and at least one copy of a miR-122 target sequence inserted into the ICP27 locus of the recombinant HSV genome.
A recombinant herpes simplex virus (HSV) comprising:
- at least one copy of a micro-RNA (miR)-124 target sequence inserted into the ICP4 locus of the recombinant HSV genome and at least one copy of a miR-122 target sequence inserted into the ICP27 locus of the recombinant HSV genome;
- at least one additional miR target sequence incorporated into the ICP4 locus or the ICP27, wherein the additional miR target sequence is a sequence other than a miR-124 or a miR-122 target sequence;
- and
- a heterologous polynucleotide sequence encoding a human IL-12 protein.
A method of treating a cancer in a subject in need thereof,
- comprising administering a recombinant herpes simplex virus (HSV) to the subject, wherein the recombinant HSV comprises:
- at least one copy of a micro-RNA (miR)-124 target sequence inserted into the ICP4 locus of the recombinant HSV genome and at least one copy of a miR-122 target sequence inserted into the ICP27 locus of the recombinant HSV genome;
- and
- a heterologous polynucleotide sequence encoding a human IL-12 protein,
- thereby treating the cancer.
A method of treating a cancer in a subject in need thereof,
- comprising administering a recombinant herpes simplex virus (HSV) to the subject, wherein the recombinant HSV comprises at least one copy of a micro-RNA (miR)-124 target sequence inserted into the ICP4 locus of the recombinant HSV genome and at least one copy of a miR-122 target sequence inserted into the ICP27 locus of the recombinant HSV genome, thereby treating the cancer.
Dependencies are inferred from the claim text.